AGN 211745
Alternative Names: AGN-211745; AGN-745; Sirna 027Latest Information Update: 18 May 2020
At a glance
- Originator Sirna Therapeutics
- Developer Allergan
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 13 Feb 2007 Phase-II clinical trials in Age-related macular degeneration in USA (Intravitreous)
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co